ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Clinical Efficacy of Shockwave Therapy in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 207559" data-attributes="member: 13851"><p><strong>Purpose:</strong> <em>To assess the safety and effect of the multifocal low-intensity extracorporeal shockwave therapy (MESWT) in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).</em></p><p></p><p><strong>Materials and Methods:</strong> <em>We randomly separated 30 patients with CP/CPPS into a MESWT and placebo group of the same number using a prospective-randomized, double-blind design. The participants’ National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total and subdomain scores, International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and visual analog scale (VAS) were assessed and compared at baseline and at finishing immediately and 4 weeks after the procedure and also were compared between MESWT and placebo groups. </em></p><p></p><p><strong>Results: </strong><em>A total of 30 participants were randomized to a MESWT or placebo group. Twenty of thirty participants completed this trial. NIH-CPSI total and subdomain scores, IPSS, IIEF-5, and VAS had significantly ameliorated compared with baseline in the MESWT group at 4 weeks assessment. Furthermore, a comparison of the results from MESWT and placebo groups represented statistically significant differences in NIH-CPSI total and subdomain scores, IPSS, IIEF-5, and VAS. No side effects or events have occurred in both groups of the participants during study periods.</em></p><p></p><p><strong>Conclusions:</strong> <em>MESWT can be an effective treatment modality in patients with CP/CPPS as it improves pain and QoL.</em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em></em></p><p><em><strong>Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) is a frequent urologic disease in male [1,2].</strong> National Institutes of Health (NIH) category III CP/CPPS is the most common subtype of prostatitis, with heterogeneous and mainly uncertain causes.</em><strong><em> Inflammatory and non-inflammatory CP/CPPS is distinguished according to the clinical presentation of patients, the absence or presence of white blood cells or bacteria in the expressed prostate secretion (EPS), post prostatic massage urine or seminal fluid [3,4]. <u>The major symptoms of this disease contain persistent and recurrent pelvic floor, lower abdomen, perineum, scrotum, and penis pain and discomfort, various degrees of lower urinary tract symptoms such as dysuria, frequency, urgency and sense of incomplete urination</u>.</em></strong></p><p></p><p>Many studies represented that CP/CPPS III patients have been suffered for a long time without treatment. Furthermore, there is no standard therapy of CP/CPPS until a recent date [5,6].<strong><em> Various treatment options are suggested, like antibiotics, non-steroidal anti-inflammatory agents, α-blocker, and non-medical modalities (electromagnetic therapy, physiotherapy, neuromodulatory therapy, intraprostatic injection, and transcutaneous electrical nerve stimulation). However, any of these therapy modalities did not reveal a significant success rate [2,7,8].</em></strong></p><p><strong><em></em></strong></p><p><strong><em>Several studies have recently reported the effectiveness and safety of low-intensity extracorporeal shock wave therapy (Li-ESWT) for patients with CP/CPPS [9-12]. <u>However, these studies almost utilized uni-focal ESWT for the treatment of CP/CPPS</u>. <u>Recently, multifocal low-intensity extracorporeal shock wave therapy (MESWT) was invented and manufactured in Korea</u>. <u>The main feature of MESWT is that the treatment effect can be increased by expanding the shockwave therapy zone</u>. </em></strong><em>To our knowledge, there was no study to evaluate the efficacy and safety MESWT for the treatment of CP/CPPS. This present study uses randomized controlled design in order to assess the exact effect of MESWT on the clinical effectiveness and safety of CP/ CPPS.</em></p><p></p><p></p><p></p><p></p><p><strong>CONCLUSIONS </strong></p><p><strong></strong></p><p><strong><em>Our study results confirmed the efficacy and safety of MESWT in cases of CP/CPPS in the short term. MESWT is cost-effective, easy to conduct, and prevents side effects. MESWT is a local treatment with the opportunity of repeating the treatment at all times. It is mandatory to perform large-number and long-term follow-up studies comparing the effectiveness of unifocal ESWT to that of MESWT.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 207559, member: 13851"] [B]Purpose:[/B] [I]To assess the safety and effect of the multifocal low-intensity extracorporeal shockwave therapy (MESWT) in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).[/I] [B]Materials and Methods:[/B] [I]We randomly separated 30 patients with CP/CPPS into a MESWT and placebo group of the same number using a prospective-randomized, double-blind design. The participants’ National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total and subdomain scores, International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and visual analog scale (VAS) were assessed and compared at baseline and at finishing immediately and 4 weeks after the procedure and also were compared between MESWT and placebo groups. [/I] [B]Results: [/B][I]A total of 30 participants were randomized to a MESWT or placebo group. Twenty of thirty participants completed this trial. NIH-CPSI total and subdomain scores, IPSS, IIEF-5, and VAS had significantly ameliorated compared with baseline in the MESWT group at 4 weeks assessment. Furthermore, a comparison of the results from MESWT and placebo groups represented statistically significant differences in NIH-CPSI total and subdomain scores, IPSS, IIEF-5, and VAS. No side effects or events have occurred in both groups of the participants during study periods.[/I] [B]Conclusions:[/B] [I]MESWT can be an effective treatment modality in patients with CP/CPPS as it improves pain and QoL. [B]Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) is a frequent urologic disease in male [1,2].[/B] National Institutes of Health (NIH) category III CP/CPPS is the most common subtype of prostatitis, with heterogeneous and mainly uncertain causes.[/I][B][I] Inflammatory and non-inflammatory CP/CPPS is distinguished according to the clinical presentation of patients, the absence or presence of white blood cells or bacteria in the expressed prostate secretion (EPS), post prostatic massage urine or seminal fluid [3,4]. [U]The major symptoms of this disease contain persistent and recurrent pelvic floor, lower abdomen, perineum, scrotum, and penis pain and discomfort, various degrees of lower urinary tract symptoms such as dysuria, frequency, urgency and sense of incomplete urination[/U].[/I][/B] Many studies represented that CP/CPPS III patients have been suffered for a long time without treatment. Furthermore, there is no standard therapy of CP/CPPS until a recent date [5,6].[B][I] Various treatment options are suggested, like antibiotics, non-steroidal anti-inflammatory agents, α-blocker, and non-medical modalities (electromagnetic therapy, physiotherapy, neuromodulatory therapy, intraprostatic injection, and transcutaneous electrical nerve stimulation). However, any of these therapy modalities did not reveal a significant success rate [2,7,8]. Several studies have recently reported the effectiveness and safety of low-intensity extracorporeal shock wave therapy (Li-ESWT) for patients with CP/CPPS [9-12]. [U]However, these studies almost utilized uni-focal ESWT for the treatment of CP/CPPS[/U]. [U]Recently, multifocal low-intensity extracorporeal shock wave therapy (MESWT) was invented and manufactured in Korea[/U]. [U]The main feature of MESWT is that the treatment effect can be increased by expanding the shockwave therapy zone[/U]. [/I][/B][I]To our knowledge, there was no study to evaluate the efficacy and safety MESWT for the treatment of CP/CPPS. This present study uses randomized controlled design in order to assess the exact effect of MESWT on the clinical effectiveness and safety of CP/ CPPS.[/I] [B]CONCLUSIONS [I]Our study results confirmed the efficacy and safety of MESWT in cases of CP/CPPS in the short term. MESWT is cost-effective, easy to conduct, and prevents side effects. MESWT is a local treatment with the opportunity of repeating the treatment at all times. It is mandatory to perform large-number and long-term follow-up studies comparing the effectiveness of unifocal ESWT to that of MESWT.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Clinical Efficacy of Shockwave Therapy in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top